biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (3155)	10/23/2014 10:43:10 AM
From: The Ox	of 3661

ADHD, down to $4.30 off 25% Piper Jaffray analyst Charles Duncan slashed his price target on Alcobra Ltd. (NASDAQ: ADHD) to $18.00 (from $42.00) but maintained a Overweight rating. Duncan commented, "On Wednesday afternoon, a well known ADHD expert presented updated analyses from the Phase III study of MDX in adult ADHD (aADHD). These data reinforce our view that MDX may prove to have a differentiated efficacy/safety profile and become a valuable addition to the aADHD treatment tool box. Recall that the study missed its primary endpoint on the intent to treat population but hit when 4 outlier patients were removed from the placebo arm. Shares are down aftermarket, likely due to additional modifications to the modified-ITT analyses which, although "sloppy" and unlikely to sway investors in the short run, probably will inform the design and conduct of next clinical studies with an effect more prominent in primarily-inattentive patients." For an analyst ratings summary and ratings history on Alcobra Ltd. click here. For more ratings news on Alcobra Ltd. click here. Shares of Alcobra Ltd. closed at $5.68 yesterday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next